Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NextCure, Inc. (NXTC)

NextCure CMO Udayan Guha to leave October 31, 2026 ahead of Avere merger

Neutral Impact 4 of 5 leadership Written later

NextCure said its Chief Medical Officer, Dr. Udayan Guha, will be terminated effective October 31, 2026, in connection with the pending merger with Avere Therapeutics, Inc. He signed a severance agreement and release, and additional change-in-control severance is payable only if the merger closes.

Key points

  • Dr. Udayan Guha, Chief Medical Officer and a named executive officer, is terminated effective October 31, 2026.
  • The departure is tied to the pending merger of NextCure and Avere Therapeutics, Inc.
  • Severance follows his existing employment agreement; enhanced change-in-control severance applies only if the merger closes.
  • The filing does not state the dollar amount of severance.

The filing

CompanyNextCure, Inc. (NXTC)
Form8-K, current report
Filed with the SECOct 30, 2026, 8:00 AM ET
Accession number0001104659-26-120405

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.